{"content":"<li class=\"n-box-item date-title\" data-end=\"1504756799\" data-start=\"1504670400\" data-txt=\"Monday, December 23, 2019\">Wednesday, September  6, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3294013\" data-ts=\"1504741278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDR\" target=\"_blank\">ALDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294013-alder-bioplus-4_3-mizuho-starts-buy-sees-244-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alder Bio +4.3% as Mizuho starts at Buy, sees 244% upside</a></h4><ul>   <li>Alder Biopharmaceuticals (<a href=\"http://seekingalpha.com/symbol/ALDR\" target=\"_blank\">ALDR</a> <font color='red'>-2.1%</font>) is <font color='green'>up 4.3%</font> in after-hours trading after Mizuho has launched coverage at Buy.</li>    <li>The firm's joining a half-dozen other bullish analysts, and set a price target of $32, nearly 3.5 times the stock's closing price of $9.30.</li>    <li>After hours, it's quoting at $9.70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294013\" data-linked=\"Alder Bio +4.3% as Mizuho starts at Buy, sees 244% upside\" data-tweet=\"$ALDR - Alder Bio +4.3% as Mizuho starts at Buy, sees 244% upside https://seekingalpha.com/news/3294013-alder-bioplus-4_3-mizuho-starts-buy-sees-244-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3294013-alder-bioplus-4_3-mizuho-starts-buy-sees-244-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294009\" data-ts=\"1504739428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATCEY\" target=\"_blank\">ATCEY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294009-moodys-skeptical-suitors-can-pull-off-charter-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moody&#39;s skeptical that suitors can pull off Charter buyout</a></h4><ul>   <li>Considering the debt that would be involved, Moody's has issued an unsurprisingly <a href=\"http://www.barrons.com/articles/charter-communications-no-deal-for-you-1504727152\" target=\"_blank\">skeptical report</a> on the odds that Charter Communications (<a href=\"http://seekingalpha.com/symbol/CHTR\" target=\"_blank\">CHTR</a> <font color='green'>+2.3%</font>) would be acquired.</li>    <li>That's despite more than its fair share of buyout chatter. Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='red'>-1%</font>) had reportedly <a href=\"https://seekingalpha.com/news/3271030-report-charter-rebuffs-100b-plus-verizon-buyout-offer-sirius-xm-eyed\" target=\"_blank\">approached with an offer of more than $100B</a> that was rebuffed; Altice (<a href='https://seekingalpha.com/symbol/ATCEY' title='ALTICE S A ADR'>OTCPK:ATCEY</a>) and Altice USA (<a href=\"http://seekingalpha.com/symbol/ATUS\" target=\"_blank\">ATUS</a> <font color='green'>+0.9%</font>) are <a href=\"https://seekingalpha.com/news/3287561\" target=\"_blank\">part of the conversation</a>; and SoftBank (<a href=\"http://seekingalpha.com/symbol/SFTBY\" target=\"_blank\">SFTBY</a> <font color='green'>+0.4%</font>) says it has <a href=\"https://seekingalpha.com/news/3283418\" target=\"_blank\">financing lined up for a bid</a>.</li>    <li>But \"in our view, an LBO would be extremely challenging, and therefore such an acquisition of Charter is unlikely,\" Moody's says, pointing to a resulting speculative-grade company with $100B-plus in debt.</li>    <li>That's aside from having to convince controlling shareholders in John Malone (via Liberty Broadband) and Advance-Newhouse, and a further integration challenge while Charter is still absorbing legacy operations from Time Warner Cable and Bright House Networks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294009\" data-linked=\"Moody&#39;s skeptical that suitors can pull off Charter buyout\" data-tweet=\"$ATCEY $ATCEY $CHTR - Moody&#39;s skeptical that suitors can pull off Charter buyout https://seekingalpha.com/news/3294009-moodys-skeptical-suitors-can-pull-off-charter-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3294009-moodys-skeptical-suitors-can-pull-off-charter-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294005\" data-ts=\"1504736803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YUME\" target=\"_blank\">YUME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294005-yumeplus-3_3-filing-details-singer-stake-buyout-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YuMe +3.3% as filing details Singer stake with buyout ahead</a></h4><ul>   <li>YuMe (<a href=\"http://seekingalpha.com/symbol/YUME\" target=\"_blank\">YUME</a> <font color='red'>-7.7%</font>) is <font color='green'>up 3.3%</font> after hours after an <a href=\"https://seekingalpha.com/filing/3689410\" target=\"_blank\">amended statement</a> of beneficial ownership shows current stakes held by VIEX Opportunities and Eric Singer.</li>    <li>The filing is tied to the company's <a href=\"https://seekingalpha.com/news/3293435-rhythmone-acquires-yume\" target=\"_blank\">planned acquisition by RhythmOne</a>.</li>    <li>VIEX Opportunities Fund Series One is beneficial owner of a 7.5% stake (just under 2.592M shares), and its Series Two is owner of a 1.6% stake. VIEX Special Opportunities Fund II holds a 6.8% stake.</li>    <li>As general partner of Series One and Series Two, VIEX GP holds 9.1%. VIEX Special Opportunities GP II (as general partner of Special Opportunities II) holds 6.8%.</li>    <li>Then as the umbrella investment manager, VIEX Capital Advisors (and thus Eric Singer) holds 15.9% -- 5,508,069 shares.</li>    <li>Singer has entered into a support agreement for the acquisition.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294005\" data-linked=\"YuMe +3.3% as filing details Singer stake with buyout ahead\" data-tweet=\"$YUME - YuMe +3.3% as filing details Singer stake with buyout ahead https://seekingalpha.com/news/3294005-yumeplus-3_3-filing-details-singer-stake-buyout-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3294005-yumeplus-3_3-filing-details-singer-stake-buyout-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293999\" data-ts=\"1504733901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293999-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color='green'>+38.1%</font>. <a href='https://seekingalpha.com/symbol/AMSC' title='American Superconductor Corporation'>AMSC</a> <font color='green'>+17.9%</font>. <a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a> <font color='green'>+5.0%</font>. <a href='https://seekingalpha.com/symbol/YUME' title='YuMe, Inc.'>YUME</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+2.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/NCS' title='NCI Building Systems Inc.'>NCS</a> <font color='red'>-12.5%</font>. <a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='red'>-4.6%</font>. <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='red'>-1.8%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/OSB' title='Norbord Inc.'>OSB</a> <font color='red'>-1.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293999\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$RH $AMSC $VRNT - After Hours Gainers / Losers https://seekingalpha.com/news/3293999-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3293999-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293991\" data-ts=\"1504732251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNV\" target=\"_blank\">SNV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293991-fed-approves-sale-of-cabelas-credit-card-unit-shares-jump-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fed approves sale of Cabela&#39;s credit-card unit; shares jump 14%</a></h4><ul><li><a href=\"https://www.federalreserve.gov/newsevents/pressreleases/orders20170906a.htm\" target=\"_blank\">The Federal Reserve has</a> green-lit Synovus' (NYSE:<a href='https://seekingalpha.com/symbol/SNV' title='Synovus Financial Corp.'>SNV</a>) purchase of World's Foremost Bank.</li><li>The deal is part of the $5B buyout of Bass Pro Shops. Synovus, in turn, will sell the credit-card operation to Capital One (NYSE:<a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a>), while keeping the &nbsp;bank's $1.2B in deposits.</li><li><a href='https://seekingalpha.com/symbol/CAB' title='Cabela&#39;s Incorporated'>CAB</a>&nbsp;<font color='green'>+14.25%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3293991\" data-linked=\"Fed approves sale of Cabela&#39;s credit-card unit; shares jump 14%\" data-tweet=\"$SNV $SNV $COF - Fed approves sale of Cabela&#39;s credit-card unit; shares jump 14% https://seekingalpha.com/news/3293991-fed-approves-sale-of-cabelas-credit-card-unit-shares-jump-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3293991-fed-approves-sale-of-cabelas-credit-card-unit-shares-jump-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293980\" data-ts=\"1504731151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAC\" target=\"_blank\">SEAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293980-seachangeplus-2_3-on-smaller-loss-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SeaChange +2.3% on smaller loss than expected</a></h4><ul>   <li>Video streamer service firm SeaChange International (NASDAQ:<a href='https://seekingalpha.com/symbol/SEAC' title='SeaChange International, Inc.'>SEAC</a>) is <font color='green'>up 2.3%</font> in postmarket trade after posting <a href=\"https://seekingalpha.com/news/3293951-seachange-beats-0_03-misses-revenue\" target=\"_blank\">Q2 earnings</a> where it posted a smaller-than-expected loss, though revenues fell nearly 7%.</li>    <li>In Q2, \"we saw continued success with existing and new customers for IP video and cloud-based deployments, including the first sale of our new NitroX platform,\" says CEO Ed Terino. \"We are continuing to generate green field customer opportunities globally for our end-to-end subscription solution, with yet another new multimillion-dollar transaction in the quarter, which provides stronger support for revenue growth next year.\"</li>    <li>Cash, equivalents, restricted cash and marketable securities came to $36M against no debt.</li>    <li>It's guiding to Q3 revenues of $19M-$21M  and non-GAAP income from operations of break-even to a $0.03 gain.</li>    <li>For the full year, \"because larger transactions are moving to a subscription model,\" it's lowered (and narrowed) expectations for revenue to $75M-$80M, and non-GAAP operating income of -$0.03 to $0.02.</li>    <li><a href=\"www.schange.com/IR\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16933341-seachange-international-reports-second-quarter-fiscal-2018-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3293980\" data-linked=\"SeaChange +2.3% on smaller loss than expected\" data-tweet=\"$SEAC - SeaChange +2.3% on smaller loss than expected https://seekingalpha.com/news/3293980-seachangeplus-2_3-on-smaller-loss-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3293980-seachangeplus-2_3-on-smaller-loss-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293971\" data-ts=\"1504729959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293971-rh-soars-after-lifting-full-year-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RH soars after lifting full-year guidance</a></h4><ul>     <li>RH (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>) races higher after topping FQ4 estimates and lifting full-year guidance.</li><li>CEO Gary Friedman says \"temporal issues\" held back results during the quarter, but sees cash flow improvement in the new fiscal year.</li>     <li>The retailer sees FY18 revenue of $2.42B to $2.46B vs. $2.40B to $2.45B prior and $2.44B consensus. The view for full-year EPS is $2.43 to $2.67 vs. $1.67 to $1.94 prior and $2.09 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293953-rh-beats-0_18-beats-revenue\" target=\"_blank\">RH beats by $0.18, beats on revenue</a> (Sept. 6)</li><li>RH +37.60% AH to $68.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293971\" data-linked=\"RH soars after lifting full-year guidance\" data-tweet=\"$RH - RH soars after lifting full-year guidance https://seekingalpha.com/news/3293971-rh-soars-after-lifting-full-year-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3293971-rh-soars-after-lifting-full-year-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293968\" data-ts=\"1504729638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNT\" target=\"_blank\">VRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293968-verint-beats-q2-estimates-announces-death-of-board-chairman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verint beats Q2 estimates, announces death of board chairman</a></h4><ul><li>Verint Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a>)&nbsp;shares&nbsp;<font color='green'>up &nbsp;5.45%</font>&nbsp;aftermarket after announcing Q2 revenue and EPS beats.</li><li>In a separate announcement, the company revealed that board chairman Victor DeMarines passed away on August 30. DeMarines joined the board in 2002 before the IPO.</li><li>President and CEO Dan Bodner has stepped into the chairman role after a unanimous vote.</li><li>Earnings <a href=\"https://seekingalpha.com/pr/16933333-verint-reports-second-quarter-results\" target=\"_blank\">press release</a> / board <a href=\"https://seekingalpha.com/pr/16933347-verint-announces-passing-chairman-victor-demarines\" target=\"_blank\">press release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3293945-verint-systems-beats-0_14-beats-revenue\" target=\"_blank\">Verint Systems beats by $0.14, beats on revenue</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293968\" data-linked=\"Verint beats Q2 estimates, announces death of board chairman\" data-tweet=\"$VRNT - Verint beats Q2 estimates, announces death of board chairman https://seekingalpha.com/news/3293968-verint-beats-q2-estimates-announces-death-of-board-chairman?source=tweet\" data-url=\"https://seekingalpha.com/news/3293968-verint-beats-q2-estimates-announces-death-of-board-chairman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293953\" data-ts=\"1504728541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293953-rh-beats-0_18-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RH beats by $0.18, beats on revenue</a></h4><ul><li>RH (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>): Q2 EPS of $0.65 <font color='green'>beats by $0.18</font>.</li><li>Revenue of $615.33M (+13.2% Y/Y) <font color='green'>beats by $8.97M</font>.</li><li>Shares <font color='green'>+18%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16933336-rh-reports-second-quarter-fiscal-2017-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293953\" data-linked=\"RH beats by $0.18, beats on revenue\" data-tweet=\"$RH - RH beats by $0.18, beats on revenue https://seekingalpha.com/news/3293953-rh-beats-0_18-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3293953-rh-beats-0_18-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293952\" data-ts=\"1504728525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293952-amazon-kohls-deal-long-term-twist\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon-Kohl&#39;s deal could have long-term twist</a></h4><ul>     <li>Baird thinks today's announcement of a partnership between Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) and Kohl's (NYSE:<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a>) could have added significance down the road.</li><li>While the placement of&nbsp;Amazon Smart Home Experience spaces inside of Kohl's stores is small on the financial side, a play to add Kohl's high mix of &nbsp;prime \"off-mail\" retail stores would be a giant move for the e-commerce giant as it enters the fashion industry.</li><li>Shares of Kohl's ended the day&nbsp;<font color='green'>up 4.90%.</font></li><li>Source: Bloomberg</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3293779-kohls-higher-announcing-amazon-store-deal\" target=\"_blank\">Kohl's higher after announcing Amazon store deal</a> (Sept. 6)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293952\" data-linked=\"Amazon-Kohl&#39;s deal could have long-term twist\" data-tweet=\"$AMZN $AMZN $KSS - Amazon-Kohl&#39;s deal could have long-term twist https://seekingalpha.com/news/3293952-amazon-kohls-deal-long-term-twist?source=tweet\" data-url=\"https://seekingalpha.com/news/3293952-amazon-kohls-deal-long-term-twist\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293945\" data-ts=\"1504728388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNT\" target=\"_blank\">VRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293945-verint-systems-beats-0_14-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verint Systems beats by $0.14, beats on revenue</a></h4><ul><li>Verint Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a>): Q2 EPS of $0.61 <font color='green'>beats by $0.14</font>.</li><li>Revenue of $274.77M (+4.9% Y/Y) <font color='green'>beats by $5.22M</font>.</li><li>Shares <font color='green'>+3%</font>.</li><li><a href='https://seekingalpha.com/pr/16933333-verint-reports-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293945\" data-linked=\"Verint Systems beats by $0.14, beats on revenue\" data-tweet=\"$VRNT - Verint Systems beats by $0.14, beats on revenue https://seekingalpha.com/news/3293945-verint-systems-beats-0_14-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3293945-verint-systems-beats-0_14-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293936\" data-ts=\"1504726570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSM\" target=\"_blank\">TSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293936-taiwan-semiconductor-hits-back-anticompetitive-practice-accusations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Taiwan Semiconductor hits back at anticompetitive practice accusations</a></h4><ul><li>        Taiwan Semiconductor (NYSE:<a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a>) <a href=\"https://seekingalpha.com/filing/3665184\" target=\"_blank\">issues a statement</a> via a regulatory filing that responds to media claims the company has engaged in anticompetitive behavior.</li><li>                  Statement, in part: &ldquo;TSMC always respects and obeys the law. We take seriously any allegation that is brought to our attention. Our procedures, employee training and control mechanisms are established to ensure that we comply with all legal rules and regulations. The semiconductor industry is a highly dynamic and competitive industry, which means TSMC is constantly having to work hard, to make investments in R&amp;D and capacity, and to deliver high quality and innovative services to our customers. Therefore, we believe any allegation accusing us of engaging in any anticompetitive conduct is without merit.&rdquo;    </li><li>               The company continues on to say that any regulatory agency requests will receive a cooperative response but that Taiwan Semiconductor has not received any request of that nature.&nbsp;</li><li>               TSM shares are&nbsp;<font color='green'>up 1.25%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291558-semiconductor-capital-spending-grow-27-percent-year-depending-samsung\" target=\"_blank\">Semiconductor capital spending could grow 27% this year, depending on Samsung</a> (Aug. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293936\" data-linked=\"Taiwan Semiconductor hits back at anticompetitive practice accusations\" data-tweet=\"$TSM - Taiwan Semiconductor hits back at anticompetitive practice accusations https://seekingalpha.com/news/3293936-taiwan-semiconductor-hits-back-anticompetitive-practice-accusations?source=tweet\" data-url=\"https://seekingalpha.com/news/3293936-taiwan-semiconductor-hits-back-anticompetitive-practice-accusations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293933\" data-ts=\"1504726170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293933-csx-higher-disruptions-in-back-mirror\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX higher with disruptions in back mirror</a></h4><ul><li>Shares of CSX (NYSE:<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a>) turn around from a premarket dip as investors weigh CEO Hunter Harrison's <a href=\"https://www.bloomberg.com/gadfly/articles/2017-09-06/csx-disruptions-weren-t-as-overplayed-as-advertised\" target=\"_blank\">assessment </a>that many of the operational challenges the railroad faced are behind it.</li><li>CSX lowered its full-year guidance due in part to those services issues earlier this summer, but shares are&nbsp;<font color='green'>up 2.76%</font>&nbsp;on the day.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293803-csx-1_5-percent-trimming-outlook\" target=\"_blank\">CSX down 1.5% after trimming outlook</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293933\" data-linked=\"CSX higher with disruptions in back mirror\" data-tweet=\"$CSX - CSX higher with disruptions in back mirror https://seekingalpha.com/news/3293933-csx-higher-disruptions-in-back-mirror?source=tweet\" data-url=\"https://seekingalpha.com/news/3293933-csx-higher-disruptions-in-back-mirror\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293931\" data-ts=\"1504724674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PYDS\" target=\"_blank\">PYDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293931-payment-data-systems-acquires-singular-payments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Payment Data Systems acquires Singular Payments</a></h4><ul>     <li>Payment Data Systems (<a href='https://seekingalpha.com/symbol/PYDS' title='Payment Data Systems, Inc.'>PYDS</a> <font color='red'>-8.6%</font>) announced that the acquisition of Singular Payments was finalized on Sept. 1, 2017. The Company funded the transaction with a combination of cash and common stock, for a total consideration of $5M.</li>     <li>The acquisition will add over 1,200 new merchant customers, which are primarily health care related, and over $500M in annual payment processing volume to Payment Data Systems.</li>     <li>The company expect Singular to immediately contribute over $10M in annualized revenue and 10%-15% increase in revenue in Q317 (Y/Y). The company also expects to record all-time high revenues in the Q417.</li>     <li>CEO Louis Hoch; \"We are thrilled that we have closed this transaction and are now able to realize the associated value that Singular brings.  This strategic acquisition will accelerate our growth and is consistent with our strategic plans to grow the revenues of our Company, Singular has a proven track record of winning new business, and we will leverage their sales excellence to enhance market share for our innovative products and services that their clients may have not been exposed to yet.  Similarly, we intend to offer their products to our customers. The combination of the two companies should create an entity that delivers on revenue growth.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293931\" data-linked=\"Payment Data Systems acquires Singular Payments\" data-tweet=\"$PYDS $USIO - Payment Data Systems acquires Singular Payments https://seekingalpha.com/news/3293931-payment-data-systems-acquires-singular-payments?source=tweet\" data-url=\"https://seekingalpha.com/news/3293931-payment-data-systems-acquires-singular-payments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293923\" data-ts=\"1504724196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293923-abc-rides-football-to-top-nbc-in-prime-time-ratings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ABC rides football to top NBC in prime-time ratings</a></h4><ul>   <li>ABC (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='green'>+0.1%</font>) <a href=\"http://wtop.com/ncaa-football/2017/09/college-football-helps-abc-win-in-television-ratings/\" target=\"_blank\">moved to the top</a> of broadcast prime-time ratings this week, past NBC (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+0.9%</font>), thanks to the return of college football.</li>    <li>ABC averaged 4.61M viewers in prime time, while NBC rode its workhorse <i>America's Got Talent</i> to 4.59M on average. They were followed by CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='red'>-2%</font>), with 3.9M; Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-1.2%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-1.4%</font>) with 2.3M; and Univision (<a href='https://seekingalpha.com/symbol/UVN' title='Univision'>UVN</a>) and Telemundo, with 1.41M.</li>    <li>A marquee night game between No. 1-ranked Alabama and No. 3 Florida State drew some <i>AGT</i>-like numbers for ABC, with 12.34M viewers, good for second place for the week just behind the Tuesday <i>AGT</i> (13.13M). Following them in the top five programs: a Wednesday broadcast of <i>America's Got Talent</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>), with 11.09M; <i>College Football Pre-Game</i> on ABC, 7.4M; and 60 Minutes (NYSE:<a href='https://seekingalpha.com/symbol/CBS' title='CBS Corporation'>CBS</a>), with 7.05M.</li>    <li>In cable ratings, Fox News prevailed again with 2.13M prime-time viewers, ahead of ESPN's 1.78M, MSNBC's 1.75M, USA Network (<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) with 1.59M and HGTV (NYSE:<a href='https://seekingalpha.com/symbol/SNI' title='Scripps Networks Interactive, Inc.'>SNI</a>) with 1.36M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293923\" data-linked=\"ABC rides football to top NBC in prime-time ratings\" data-tweet=\"$FOX $FOX $FOXA - ABC rides football to top NBC in prime-time ratings https://seekingalpha.com/news/3293923-abc-rides-football-to-top-nbc-in-prime-time-ratings?source=tweet\" data-url=\"https://seekingalpha.com/news/3293923-abc-rides-football-to-top-nbc-in-prime-time-ratings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293922\" data-ts=\"1504724104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293922-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/LDR' title='Landauer, Inc.'>LDR</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SCWX' title='SecureWorks Corp.'>SCWX</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TRVG' title='Trivago'>TRVG</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SREV' title='ServiceSource International, Inc.'>SREV</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BSQR' title='BSQUARE Corporation'>BSQR</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293922\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$OPNT $EFII $LDR - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3293922-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293922-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293919\" data-ts=\"1504723001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACN\" target=\"_blank\">ACN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293919-accenture-acquires-connected-product-design-firm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Accenture acquires connected product design firm</a></h4><ul><li>        Accenture (NYSE:<a href='https://seekingalpha.com/symbol/ACN' title='Accenture plc'>ACN</a>) announces the acquisition of connected product design and innovation firm MATTER.</li><li>               No financial terms disclosed.&nbsp;</li><li>                  MATTER&rsquo;s lead product is the Cujo firewall product for smart housing device security.    </li><li>               The acquisition will strengthen Accenture Interactive&rsquo;s Fjord design and innovation consultancy unit, which was acquired four years ago.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16933114-accenture-acquires-leading-design-and-innovation-firm-matter\" target=\"_blank\">Press release</a>&nbsp;</li><li>               Accenture shares are&nbsp;<font color='green'>up 1.16%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293884-accenture-announces-consulting-firm-acquisition\" target=\"_blank\">Accenture announces consulting firm acquisition</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293919\" data-linked=\"Accenture acquires connected product design firm\" data-tweet=\"$ACN - Accenture acquires connected product design firm https://seekingalpha.com/news/3293919-accenture-acquires-connected-product-design-firm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293919-accenture-acquires-connected-product-design-firm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293916\" data-ts=\"1504722217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSRA\" target=\"_blank\">CSRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293916-csra-announces-2_4b-nsa-groundbreaker-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSRA announces $2.4B NSA Groundbreaker contract</a></h4><ul><li>        CSRA (NYSE:<a href='https://seekingalpha.com/symbol/CSRA' title='CSRA Inc.'>CSRA</a>) and its Eagle Alliance joint venture announce receiving a potential 10-year, $2.4B contract with the U.S. National Security Agency.</li><li>               The award relates to the enterprise IT service portion of the NSA&rsquo;s Groundbreaker contract.&nbsp;</li><li>               CSRA initially won a $5B Groundbreaker award in 2001. Groundbreaker accounts for about 7% of CSRA&rsquo;s total annual revenue.&nbsp;</li><li>               The Eagle Alliance joint venture also includes Northrop Grumman but CSRA owns 79% of the venture.&nbsp;</li><li>               <a href=\"https://washingtontechnology.com/articles/2017/09/05/crsa-greenway-win.aspx?m=1\" target=\"_blank\">Press release</a>&nbsp;</li><li>               CSRA shares are&nbsp;<font color='green'>up 3.8%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292109-csra-announces-115m-epa-contract\" target=\"_blank\">CSRA announces $115M EPA contract</a> (Aug. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293916\" data-linked=\"CSRA announces $2.4B NSA Groundbreaker contract\" data-tweet=\"$CSRA - CSRA announces $2.4B NSA Groundbreaker contract https://seekingalpha.com/news/3293916-csra-announces-2_4b-nsa-groundbreaker-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3293916-csra-announces-2_4b-nsa-groundbreaker-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293911\" data-ts=\"1504720852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293911-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/TELL' title='Tellurian Inc.'>TELL</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a> <font color='green'>+7%</font>. SGY <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293911\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$LTBR $TELL $PES - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3293911-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293911-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293900\" data-ts=\"1504718379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTVT\" target=\"_blank\">VTVT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293900-leading-funding-group-on-board-support-for-mid-stage-study-of-vtv-therapeutics-ttp399-for\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leading funding group on board with support for mid-stage study of vTv Therapeutics&#39; TTP399 for type 1 diabetes; shares down 5% on profit-taking</a></h4><ul><li>Global funding organization JDRF has committed $3M to support a Phase 2 proof-of-concept study to assess vTv Therapeutics' (<a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='red'>-5.3%</font>) liver-selective glucokinase &#40;GK&#41; activator TTP399 in type 1 diabetics. The trial will evaluate the tolerability of orally available TTP399 as an add-on to insulin therapy in addition to its ability to help patients improve the management of their blood sugar levels. The company will also contribute $3M to the study.</li><li>The company is launching the study based on positive results observed in a mid-stage trial in type 2 diabetics.</li><li>GK is a key regulator of glucose metabolism. Activating the enzyme increases glucose utilization which, in turn, lowers blood glucose.</li><li>Investors appear to be bagging some profits since the stock had run up over 50% before correcting.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293900\" data-linked=\"Leading funding group on board with support for mid-stage study of vTv Therapeutics&#39; TTP399 for type 1 diabetes; shares down 5% on profit-taking\" data-tweet=\"$VTVT - Leading funding group on board with support for mid-stage study of vTv Therapeutics&#39; TTP399 for type 1 diabetes; shares down 5% on profit-taking https://seekingalpha.com/news/3293900-leading-funding-group-on-board-support-for-mid-stage-study-of-vtv-therapeutics-ttp399-for?source=tweet\" data-url=\"https://seekingalpha.com/news/3293900-leading-funding-group-on-board-support-for-mid-stage-study-of-vtv-therapeutics-ttp399-for\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293899\" data-ts=\"1504717848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KO\" target=\"_blank\">KO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293899-credit-suisse-sees-monster-takeout-years-off\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse sees Monster takeout a few years off</a></h4><ul> <li>Credit Suisse thinks Coca-Cola (<a href='https://seekingalpha.com/symbol/KO' title='The Coca-Cola Company'>KO</a>) won't acquire Monster Beverage (<a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a> <font color='red'>-0.5%</font>) until a few years down the road.</li> <li>The CS views runs counter to a report from TheDeal.com indicating a deal is close.</li> <li>\"In the current context of Coke wanting to portray itself as a beverage company offering healthier options to consumers, buying Monster would not help the company reassure consumers and, more importantly, governments and health associations that it's genuinely interested in its health and wellness agenda,\" reasons the CS team.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293680-monster-beverage-3-percent-takeover-chatter\" target=\"_blank\">Monster Beverage up 3% on takeover chatter</a> (Sept. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293899\" data-linked=\"Credit Suisse sees Monster takeout a few years off\" data-tweet=\"$KO $KO $MNST - Credit Suisse sees Monster takeout a few years off https://seekingalpha.com/news/3293899-credit-suisse-sees-monster-takeout-years-off?source=tweet\" data-url=\"https://seekingalpha.com/news/3293899-credit-suisse-sees-monster-takeout-years-off\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293894\" data-ts=\"1504717435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293894-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='green'>+105%</font>. <a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corp'>AAMC</a> <font color='green'>+11%</font>.<a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/FMAO' title='Farmers & Merchants Bancorp Inc.'>FMAO</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RVEN' title='Reven Housing REIT, Inc.'>RVEN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/IRT' title='Independence Realty Trust'>IRT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/MKTX' title='MarketAxess Holdings, Inc.'>MKTX</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293894\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$ZAIS $AAMC $HRTG - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3293894-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293894-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293886\" data-ts=\"1504716647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293886-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='green'>+108%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/BW' title='Babcock & Wilcox Enterprises, Inc.'>BW</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/GFF' title='Griffon Corporation'>GFF</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TRVG' title='Trivago'>TRVG</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/IRT' title='Independence Realty Trust'>IRT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LINU-OLD' title='LiNiu Technology Group'>LINU-OLD</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293886\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ZAIS $VSTM $CBIO - Midday Gainers / Losers https://seekingalpha.com/news/3293886-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3293886-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293885\" data-ts=\"1504716518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIPT\" target=\"_blank\">AIPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293885-skyline-medical-partners-intalere-to-broaden-reach-for-streamway-system-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyline Medical partners with Intalere to broaden reach for Streamway system; shares up 1%</a></h4><ul><li>Skyline Medical (SKLN <font color='green'>+0.7%</font>) inks an agreement with supply chain services outfit Intalere under which the latter will offer the STREAMWAY System in its Innovation and New Technology category to U.S. healthcare institutions and ambulatory surgical centers. Financial terms are not disclosed.</li><li><a href=\"http://www.skylinemedical.com/streamway-system/overview/\" target=\"_blank\">The STREAMWAY System</a>&nbsp;is a direct-to-drain fluid removal system used to safely remove surgical waste generated in the operating room.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293885\" data-linked=\"Skyline Medical partners with Intalere to broaden reach for Streamway system; shares up 1%\" data-tweet=\"$AIPT $POAI - Skyline Medical partners with Intalere to broaden reach for Streamway system; shares up 1% https://seekingalpha.com/news/3293885-skyline-medical-partners-intalere-to-broaden-reach-for-streamway-system-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3293885-skyline-medical-partners-intalere-to-broaden-reach-for-streamway-system-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293884\" data-ts=\"1504716254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACN\" target=\"_blank\">ACN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293884-accenture-announces-consulting-firm-acquisition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Accenture announces consulting firm acquisition</a></h4><ul><li>        Accenture (NYSE:<a href='https://seekingalpha.com/symbol/ACN' title='Accenture plc'>ACN</a>) announces signing an acquisition agreement for IBB Consulting to strengthen the company&rsquo;s ability to advise communication, media, and technology clients.</li><li>               About 160 of IBB&rsquo;s staff will join Accenture Strategy CMT after the acquisition is finalized.&nbsp;</li><li>                  Financial terms not disclosed.    </li><li>               <a href=\"https://seekingalpha.com/pr/16933046-accenture-acquire-ibb-consulting-expand-accenture-strategy-capabilities-communications-media\" target=\"_blank\">Press release</a>&nbsp;</li><li>               Accenture shares are&nbsp;<font color='green'>up 1.04%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292384-apple-accenture-announce-ios-enterprise-partnership\" target=\"_blank\">Apple, Accenture announce iOS enterprise partnership</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293884\" data-linked=\"Accenture announces consulting firm acquisition\" data-tweet=\"$ACN - Accenture announces consulting firm acquisition https://seekingalpha.com/news/3293884-accenture-announces-consulting-firm-acquisition?source=tweet\" data-url=\"https://seekingalpha.com/news/3293884-accenture-announces-consulting-firm-acquisition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293881\" data-ts=\"1504715523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPTH\" target=\"_blank\">BPTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293881-bio-path-operating-chief-bids-adieu-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bio-Path operating chief bids adieu; shares down 3%</a></h4><ul><li>Bio-Path Holdings (<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a> <font color='red'>-2.8%</font>) <a href=\"https://seekingalpha.com/filing/3688698\" target=\"_blank\">reports </a>that Chief Operating Officer Ulrich Mueller, Ph.D. resigned yesterday for undisclosed reasons.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293881\" data-linked=\"Bio-Path operating chief bids adieu; shares down 3%\" data-tweet=\"$BPTH - Bio-Path operating chief bids adieu; shares down 3% https://seekingalpha.com/news/3293881-bio-path-operating-chief-bids-adieu-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3293881-bio-path-operating-chief-bids-adieu-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293878\" data-ts=\"1504715095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293878-moleculin-teams-up-u-bergen-to-test-wp1122-avastin-combo-in-brain-cancer-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin teams up with U. Bergen to test WP1122/Avastin combo in brain cancer; shares ahead 5%</a></h4><ul><li>Moleculin Biotech (<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+5.2%</font>) perks up, albeit light volume, in response to its <a href=\"https://seekingalpha.com/pr/16932112-moleculin-collaborate-combining-wp1122-brain-cancer-drug-candidate-roches-drug-avastin\" target=\"_blank\">announcement </a>of a collaboration with the University of Bergen to evaluate the combination of WP1122 and Roche's Avastin (bevacizumab) for the treatment of brain tumors.</li><li>CEO Walter Klemp says, \"The potential for synergy with Roche's drug is compelling. Avastin showed early promise in the treatment of brain tumors, but its usefulness has been hampered by the ability of brain tumors to develop resistance to anti-vascular therapy. Avastin prevents formation of new blood vessels including blood vessels that feed growing tumors and, as such, creates an environment where tumors become more dependent on glycolysis (a means of producing energy induced by a limited oxygen supply from the blood) enabling a potential form of therapy resistance. We've shown in animal models that WP1122 as an inhibitor of glycolysis limits tumor growth and increases survival in animals transplanted with human brain tumors, so it is logical to consider that WP1122 could potentially be an effective way to deal with Avastin resistance, as a follow up treatment, or in combination with Avastin.\"</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293878\" data-linked=\"Moleculin teams up with U. Bergen to test WP1122/Avastin combo in brain cancer; shares ahead 5%\" data-tweet=\"$MBRX - Moleculin teams up with U. Bergen to test WP1122/Avastin combo in brain cancer; shares ahead 5% https://seekingalpha.com/news/3293878-moleculin-teams-up-u-bergen-to-test-wp1122-avastin-combo-in-brain-cancer-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3293878-moleculin-teams-up-u-bergen-to-test-wp1122-avastin-combo-in-brain-cancer-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293877\" data-ts=\"1504714375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293877-opiant-pharma-continues-rally-shares-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opiant Pharma continues rally, shares up 14%</a></h4><ul><li>Thinly traded nano cap Opiant Pharmaceuticals (<a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+14.4%</font>) continues its upward march. Shares have ballooned seven-fold since July. The company develops treatments for substance abuse and eating disorders.</li><li>The stock began trading on Nasdaq Capital Market on August 29. A few weeks before that, it announced the receipt of another $3.75M from its NARCAN royalty deal with SWK Holdings. NARCAN is the only FDA-approved nasal spray for the emergency treatment of opioid overdose. As the agreement matures and sales continue to ramp, the company will receive a greater share of royalties and milestones (at least 90%).</li><li>A new CFO, David O'Toole will <a href=\"https://seekingalpha.com/pr/16930459-opiant-pharmaceuticals-inc-announces-appointment-david-o-toole-chief-financial-officer\" target=\"_blank\">join the company</a> on September 12. The same day, CEO Roger Crystal, M.D., will deliver a <a href=\"https://seekingalpha.com/pr/16932018-opiant-pharmaceuticals-inc-present-rodman-and-renshaw-19th-annual-global-investment\" target=\"_blank\">corporate presentation</a> at the Rodman &amp; Renshaw Investment Conference in New York.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288186-opiant-receives-another-3_75m-narcan-royalty-deal\" target=\"_blank\">Opiant receives another $3.75M from Narcan royalty deal</a> (Aug. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293877\" data-linked=\"Opiant Pharma continues rally, shares up 14%\" data-tweet=\"$OPNT - Opiant Pharma continues rally, shares up 14% https://seekingalpha.com/news/3293877-opiant-pharma-continues-rally-shares-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3293877-opiant-pharma-continues-rally-shares-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293874\" data-ts=\"1504713652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293874-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/VRTV' title='Veritiv'>VRTV</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/NOMD' title='Nomad Foods Ltd.'>NOMD</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293874\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$LFVN $GIII $VRTV - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3293874-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293874-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293869\" data-ts=\"1504712585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZGNX\" target=\"_blank\">ZGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293869-zogenix-breaks-out-of-consolidation-on-high-volume-shares-up-15-ahead-of-data-readout-on-lead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zogenix breaks out of consolidation on high volume; shares up 15% ahead of data readout on lead candidate ZX008</a></h4><ul><li>Thinly traded micro cap Zogenix (<a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a> <font color='green'>+14.6%</font>) is showing bullish action this morning. Shares have cleared near-term resistance of $13 on a 5x surge in volume.</li><li>A key looming event is the release of top-line data from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02682927?cond=Dravet+Syndrome&amp;intr=zx008&amp;spons=zogenix&amp;phase=2&amp;rank=3\" target=\"_blank\">Study 1</a>, assessing lead candidate ZX008 (low-dose fenfluramine) in young adults with a rare and severe form of epilepsy called Dravet syndrome. According to ClinicalTrials.gov, the estimated study completion date was September 1.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3261228-last-patient-randomized-zogenixs-late-stage-study-zx008-dravet\" target=\"_blank\">Last patient randomized in Zogenix's late-stage study of ZX008 in Dravet</a> (April 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293869\" data-linked=\"Zogenix breaks out of consolidation on high volume; shares up 15% ahead of data readout on lead candidate ZX008\" data-tweet=\"$ZGNX - Zogenix breaks out of consolidation on high volume; shares up 15% ahead of data readout on lead candidate ZX008 https://seekingalpha.com/news/3293869-zogenix-breaks-out-of-consolidation-on-high-volume-shares-up-15-ahead-of-data-readout-on-lead?source=tweet\" data-url=\"https://seekingalpha.com/news/3293869-zogenix-breaks-out-of-consolidation-on-high-volume-shares-up-15-ahead-of-data-readout-on-lead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293868\" data-ts=\"1504712327\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVGW\" target=\"_blank\">CVGW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293868-post-earning-gain-for-calavo-growers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earning gain for Calavo Growers</a></h4><ul> <li>Calavo Growers (<a href='https://seekingalpha.com/symbol/CVGW' title='Calavo Growers, Inc.'>CVGW</a> <font color='green'>+3.8%</font>) rallies after topping <a href=\"https://seekingalpha.com/pr/16932538-calavo-growers-inc-announces-fiscal-2017-third-quarter-results\" target=\"_blank\">FQ3</a> sales estimates.</li> <li>The company also reaffirmed its expectation for double-digit revenue growth and higher gross margin dollars for FY17.</li> <li>Avocado outlook: \"We anticipate that there will be a significantly larger supply of avocados in fiscal 2018, including a large crop from Mexico that is going to start in this month of September. In the coming quarters, we will continue to work on increasing throughput in the Jalisco packinghouse to further enhance profitability.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293868\" data-linked=\"Post-earning gain for Calavo Growers\" data-tweet=\"$CVGW - Post-earning gain for Calavo Growers https://seekingalpha.com/news/3293868-post-earning-gain-for-calavo-growers?source=tweet\" data-url=\"https://seekingalpha.com/news/3293868-post-earning-gain-for-calavo-growers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293863\" data-ts=\"1504711620\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TECK\" target=\"_blank\">TECK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293863-teck-sees-lower-q3-steelmaking-coal-prices-sales-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teck sees lower Q3 steelmaking coal prices but more sales volume</a></h4><ul>     <li>Teck Resources (<a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='green'>+1.3%</font>) recaptures some of yesterday's 7% slide, despite saying it expects <a href=\"https://seekingalpha.com/pr/16932652-teck-updates-steelmaking-coal-guidance\" target=\"_blank\">lower average realized prices</a> for the sale of steelmaking coal during Q3.</li>     <li>Teck says it anticipates prices of $158-$163/metric ton, below the $170 benchmark price it set for the quarter.</li>     <li>However, Teck also raised its outlook for Q3 steelmaking coal sales volumes to 7.2M-7.5M metric tons from 7M tons, reflecting strong coal demand in the quarter.</li>     <li><a href=\"https://seekingalpha.com/news/3293658-teck-resources-minus-7-percent-chinese-sovereign-wealth-fund-cuts-stake\" target=\"_blank\">Yesterday</a>, Teck fell by the most among large mining stocks after China Investment Corp. unloaded nearly half its stake in the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293863\" data-linked=\"Teck sees lower Q3 steelmaking coal prices but more sales volume\" data-tweet=\"$TECK - Teck sees lower Q3 steelmaking coal prices but more sales volume https://seekingalpha.com/news/3293863-teck-sees-lower-q3-steelmaking-coal-prices-sales-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3293863-teck-sees-lower-q3-steelmaking-coal-prices-sales-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293862\" data-ts=\"1504711556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTN\" target=\"_blank\">PTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293862-palatin-tech-inks-bremelanotide-commercialization-deal-in-china-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palatin Tech inks bremelanotide commercialization deal in China; shares up 8%</a></h4><ul><li>Palatin Technologies (<a href='https://seekingalpha.com/symbol/PTN' title='Palatin Technologies, Inc'>PTN</a> <font color='green'>+7.7%</font>) enters into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Ltd. providing the latter with exclusive rights to develop and commercialize female sexual dysfunction med bremelanotide in China, Taiwan, Hong Kong and Macau.</li><li>Under the terms of the agreement, Palatin will receive $5.0M upfront, a $7.5M payment upon regulatory approval in China, up to $92.5M in sales-based milestones and high-single- to low-double-digit royalties on net sales. Fosun will be responsible for all regulatory and commercialization costs in the territory.</li><li><a href=\"http://www.palatin.com/products/bremelanotide.asp\" target=\"_blank\">Bremelanotide&nbsp;</a>is a synthetic peptide analog of the naturally occurring hormone&nbsp;<a href=\"https://en.wikipedia.org/wiki/Alpha-Melanocyte-stimulating_hormone\" target=\"_blank\">alpha-MSH</a>, a melanocortin agonist. The&nbsp;<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12556347\" target=\"_blank\">melanocortin system</a>&nbsp;plays a key role in sexual function as well as pigmentation, inflammation and energy homeostasis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293862\" data-linked=\"Palatin Tech inks bremelanotide commercialization deal in China; shares up 8%\" data-tweet=\"$PTN - Palatin Tech inks bremelanotide commercialization deal in China; shares up 8% https://seekingalpha.com/news/3293862-palatin-tech-inks-bremelanotide-commercialization-deal-in-china-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3293862-palatin-tech-inks-bremelanotide-commercialization-deal-in-china-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293858\" data-ts=\"1504710411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTOO\" target=\"_blank\">TTOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293858-t2-bio-inks-deal-cidara-to-place-t2dx-instruments-in-trial-sites-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T2 Bio inks deal with Cidara to place T2Dx instruments in trial sites; shares up 6%</a></h4><ul><li>T2 Biosystems (<a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a> <font color='green'>+6.4%</font>) extends <a href=\"https://seekingalpha.com/pr/16932077-t2-biosystems-cidara-therapeutics-announce-partnership-commercial-placement-t2dx-instruments\" target=\"_blank\">exclusive pricing</a> for its T2Dx instrument to Cidara Therapeutics (<a href='https://seekingalpha.com/symbol/CDTX' title='Cidara Therapeutics'>CDTX</a> <font color='red'>-3.2%</font>) for placement and use at its clinical trial sites for antifungal CD101. The objective of the deal is to accelerate enrollment in Cidara's clinical trials and increase the number of hospitals that adopt T2 Bio's products, including the T2Candida panel and the T2Bacteria Panel following FDA clearance.</li><li>The company will offer exclusive preferred sales terms to all U.S. trial sites for CD101 IV through the completion of the planned Phase 3 study. Cidara will reimburse sites that use the T2Candida test to screen patients for enrollment.</li><li>Specific financial terms are not disclosed.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293852-cdc-use-t2-bios-t2dx-instrument-test-superbug-candida-auris-shares-ahead-6-percent\" target=\"_blank\">CDC to use T2 Bio's T2Dx instrument to test for superbug Candida auris; shares ahead 6%</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293858\" data-linked=\"T2 Bio inks deal with Cidara to place T2Dx instruments in trial sites; shares up 6%\" data-tweet=\"$TTOO $TTOO $CDTX - T2 Bio inks deal with Cidara to place T2Dx instruments in trial sites; shares up 6% https://seekingalpha.com/news/3293858-t2-bio-inks-deal-cidara-to-place-t2dx-instruments-in-trial-sites-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3293858-t2-bio-inks-deal-cidara-to-place-t2dx-instruments-in-trial-sites-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293829\" data-ts=\"1504710109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293829-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293829\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CBIO $VSTM $VYGR - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3293829-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3293829-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293852\" data-ts=\"1504709733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTOO\" target=\"_blank\">TTOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293852-cdc-to-use-t2-bios-t2dx-instrument-to-test-for-superbug-candida-auris-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CDC to use T2 Bio&#39;s T2Dx instrument to test for superbug Candida auris; shares ahead 6%</a></h4><ul><li>T2 Biosystems (<a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a> <font color='green'>+5.5%</font>) <a href=\"https://seekingalpha.com/pr/16932048-t2-biosystems-announces-collaboration-cdc-detect-emerging-superbug-candida-auris\" target=\"_blank\">announces </a>that the U.S. Centers for Disease Control and Prevention &#40;CDC&#41; will use its T2Dx instrument to test and monitor the emergence and outbreaks of the superbug <em>Candida auris</em> in U.S. hospitals.</li><li>The company says the initiative represents a new application of the T2MR platform, which may be expanded further if new superbugs threaten.</li><li>The CDC intends to use the T2Dx to validate the detection of <em>Candida auris</em> from patient skin samples and hospital environmental samples, validate a process for <em>Candida auris</em> surveillance and assist state and local public health laboratories in combating an outbreak.</li><li>The T2Dx can generate results in 3 - 5 hours, depending on the analyte.</li><li>Shares are up&nbsp;<font color='green'>6%</font>, also helped by the company's deal with Cidara Therapeutics to place T2Dx systems in its clinical trial sites.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293852\" data-linked=\"CDC to use T2 Bio&#39;s T2Dx instrument to test for superbug Candida auris; shares ahead 6%\" data-tweet=\"$TTOO - CDC to use T2 Bio&#39;s T2Dx instrument to test for superbug Candida auris; shares ahead 6% https://seekingalpha.com/news/3293852-cdc-to-use-t2-bios-t2dx-instrument-to-test-for-superbug-candida-auris-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3293852-cdc-to-use-t2-bios-t2dx-instrument-to-test-for-superbug-candida-auris-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293848\" data-ts=\"1504709123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRT\" target=\"_blank\">IRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293848-independence-realty-down-7-after-purchase-equity-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Independence Realty down more than 7% after purchase, equity raise</a></h4><ul><li>Investors for now are focused on the dilutive effect of the capital raise, rather than accretion from the nine-property purchase.</li><li>In the <a href=\"https://seekingalpha.com/pr/16931610-independence-realty-trust-announces-agreement-acquire-portfolio-nine-communities\" target=\"_blank\">press release announcing</a> the buy, the company said the average effective rent per unit was $884 for the three months ending in July, with value-add projects already identified.</li><li>Volume today has topped 1M shares. The capital raise is for 12.5M shares.</li><li><a href='https://seekingalpha.com/symbol/IRT' title='Independence Realty Trust'>IRT</a>&nbsp;<font color='red'>-7.1%</font>&nbsp;To $9.65</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293682-independence-realty-deal-nine-property-portfolio\" target=\"_blank\">Independence Realty in deal for nine-property portfolio</a> (Sept. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293848\" data-linked=\"Independence Realty down more than 7% after purchase, equity raise\" data-tweet=\"$IRT - Independence Realty down more than 7% after purchase, equity raise https://seekingalpha.com/news/3293848-independence-realty-down-7-after-purchase-equity-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3293848-independence-realty-down-7-after-purchase-equity-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293841\" data-ts=\"1504707920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRWD\" target=\"_blank\">IRWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293841-ironwood-pharma-finance-chief-leaves-for-vertex-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ironwood Pharma finance chief leaves for Vertex; shares down 2%</a></h4><ul><li>Ironwood Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IRWD' title='Ironwood Pharmaceuticals, Inc.'>IRWD</a> <font color='red'>-1.7%</font>) SVP, Finance and Corporate Strategy Tom Graney will <a href=\"https://seekingalpha.com/pr/16932199-ironwood-pharmaceuticals-announces-leadership-change\" target=\"_blank\">resign </a>on September 13 to take the CFO job at Vertex Pharmaceuticals. VP, Finance and Chief Accounting Officer Gina Consylman will take over on an interim basis until a successor is hired.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293841\" data-linked=\"Ironwood Pharma finance chief leaves for Vertex; shares down 2%\" data-tweet=\"$IRWD - Ironwood Pharma finance chief leaves for Vertex; shares down 2% https://seekingalpha.com/news/3293841-ironwood-pharma-finance-chief-leaves-for-vertex-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3293841-ironwood-pharma-finance-chief-leaves-for-vertex-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293835\" data-ts=\"1504706870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293835-bank-of-canada-surprises-rate-hike-loonie-soars-stocks-slip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of Canada surprises with rate hike; loonie soars, stocks slip</a></h4><ul><li>\"Recent economic data have been stronger than expected,\" <a href=\"http://www.bankofcanada.ca/2017/09/fad-press-release-2017-09-06/\" target=\"_blank\">says the Bank of Canada</a>, surprising the markets by raising its benchmark overnight rate 25 basis points to 1%. It's the 2nd rate hike in as many meetings. Most economists had expected a pause.</li><li>The loonie (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXC' title='CurrencyShares Canadian Dollar Trust ETF'>FXC</a>) has<font color='green'> jumped more than 1%</font>&nbsp;vs. the greenback, now buying nearly $0.82 - its strongest level since early 2015. Stocks in Toronto have given back a few points, now roughly flat on the session.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWC' title='iShares MSCI Canada ETF'>EWC</a>, <a href='https://seekingalpha.com/symbol/CNDA' title='IQ Canada Small Cap ETF'>CNDA</a>, <a href='https://seekingalpha.com/symbol/EWCS' title='iShares MSCI Canada Small Cap Index ETF'>EWCS</a>, <a href='https://seekingalpha.com/symbol/QCAN' title='SPDR MSCI Canada Quality Mix ETF'>QCAN</a>, <a href='https://seekingalpha.com/symbol/FCAN' title='First Trust Canada AlphaDex ETF'>FCAN</a>, <a href='https://seekingalpha.com/symbol/HEWC' title='iShares Currency Hedged MSCI Canada ETF'>HEWC</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293835\" data-linked=\"Bank of Canada surprises with rate hike; loonie soars, stocks slip\" data-tweet=\"$FXC $EWC $CNDA - Bank of Canada surprises with rate hike; loonie soars, stocks slip https://seekingalpha.com/news/3293835-bank-of-canada-surprises-rate-hike-loonie-soars-stocks-slip?source=tweet\" data-url=\"https://seekingalpha.com/news/3293835-bank-of-canada-surprises-rate-hike-loonie-soars-stocks-slip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293832\" data-ts=\"1504706619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBVX\" target=\"_blank\">MBVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293832-mabvax-hires-advisor-to-assist-exploring-strategic-alternatives-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MabVax hires advisor to assist with exploring strategic alternatives; shares up 10%</a></h4><ul><li>MabVax Therapeutics Holdings (<a href='https://seekingalpha.com/symbol/MBVX' title='MABVAX THERAPEUTICS HLDGS'>OTCPK:MBVX</a> <font color='green'>+10%</font>) has <a href=\"https://seekingalpha.com/pr/16932319-mabvax-therapeutics-engages-greenhill-and-co-advisor-exploring-strategic-alternatives\" target=\"_blank\">engaged </a>Greenhill &amp; Co. to help management explore and evaluate strategic options aimed at boosting shareholder value. Alternatives include an acquisition of the company, asset sales coupled with a reverse merger, an outright merger or a licensing deal.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291101-mabvax-nets-1_3m-direct-equity-offering-will-explore-strategic-alternatives-shares-10-percent\" target=\"_blank\">MabVax nets $1.3M in direct equity offering, will explore strategic alternatives; shares up 10% after hours</a> (Aug. 22)</li><li><strong>Update</strong>: On January 16, 2018, the company <a href=\"https://seekingalpha.com/pr/17046986-mabvax-therapeutics-holdings-inc-provides-business-strategy-update\" target=\"_blank\">announced </a>that it is in advanced discussions with a range of parties for potential deals.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293832\" data-linked=\"MabVax hires advisor to assist with exploring strategic alternatives; shares up 10%\" data-tweet=\"$MBVX $MBVXQ - MabVax hires advisor to assist with exploring strategic alternatives; shares up 10% https://seekingalpha.com/news/3293832-mabvax-hires-advisor-to-assist-exploring-strategic-alternatives-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3293832-mabvax-hires-advisor-to-assist-exploring-strategic-alternatives-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293825\" data-ts=\"1504705788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293825-pulmatrix-teams-up-vectura-to-develop-copd-candidate-pur0200-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix teams up with Vectura to develop COPD candidate PUR0200; shares down 3%</a></h4><ul><li>Thinly traded nano cap Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-2.8%</font>) slumps out the blocks in response to its <a href=\"https://seekingalpha.com/pr/16932428-pulmatrix-licenses-inhaled-copd-drug-pur0200-vectura-group-plc\" target=\"_blank\">announced partnership</a> with Vectura Group plc to develop chronic obstructive pulmonary disease &#40;COPD&#41; candidate PUR0200. Investors appear disappointed that the company will not earn more under the deal.</li><li>Under the terms of the agreement, Pulmatrix will provide the data package and assist with the transfer of development and manufacturing to Vectura, who will be responsible for all future development costs to advance PUR0200 in the U.S. Pulmatrix will receive a technology access fee of $1M, contingent on the achievement of certain development criteria, and mid-teen royalties on net sales.</li><li>The value proposition of PUR0200, an improved inhaled tiotropium bromide (Boehringer Ingelheim's <a href=\"https://www.spiriva.com/asthma/\" target=\"_blank\">SPIRIVA</a>), is enhanced efficacy by virtue of its iSPERSE dry powder technology which travels more easily into the lungs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293825\" data-linked=\"Pulmatrix teams up with Vectura to develop COPD candidate PUR0200; shares down 3%\" data-tweet=\"$PULM - Pulmatrix teams up with Vectura to develop COPD candidate PUR0200; shares down 3% https://seekingalpha.com/news/3293825-pulmatrix-teams-up-vectura-to-develop-copd-candidate-pur0200-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3293825-pulmatrix-teams-up-vectura-to-develop-copd-candidate-pur0200-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293823\" data-ts=\"1504705352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOMD\" target=\"_blank\">NOMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293823-pershing-square-unloads-nomad-foods-share-block\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pershing Square unloads Nomad Foods share block</a></h4><ul>         <li>Nomad Foods (<a href='https://seekingalpha.com/symbol/NOMD' title='Nomad Foods Ltd.'>NOMD</a> <font color='red'>-3.6%</font>)&nbsp;announced a public offering of up to 33.33M shares owned by funds managed by Pershing Square.</li>     <li>Nomad is not selling shares in the offering and will not receive any of the proceeds.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16932139-nomad-foods-announces-commencement-secondary-offering-ordinary-shares-pershing-square\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3293823\" data-linked=\"Pershing Square unloads Nomad Foods share block\" data-tweet=\"$NOMD - Pershing Square unloads Nomad Foods share block https://seekingalpha.com/news/3293823-pershing-square-unloads-nomad-foods-share-block?source=tweet\" data-url=\"https://seekingalpha.com/news/3293823-pershing-square-unloads-nomad-foods-share-block\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293818\" data-ts=\"1504704556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293818-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+50%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293761-verastems-duvelisib-successful-late-stage-blood-cancer-study-shares-ahead-30-percent\" target=\"_blank\">successful</a> in late-stage blood cancer study.</li><li><a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a> <font color='green'>+27%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293813-voyagers-vy-aadc01-shows-encouraging-results-early-stage-parkinsons-study-shares-ahead-27\" target=\"_blank\">shows</a> encouraging results in early-stage Parkinson's study.</li><li><a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293771-sareptas-golodirsen-shows-treatment-effect-early-stage-study-shares-ahead-17-percent\" target=\"_blank\">treatment</a> effect in early-stage study.</li><li><a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='green'>+12%</font>&nbsp;<a href=\"https://seekingalpha.com/pr/16932059-lightbridge-areva-np-sign-binding-agreement-u-s-joint-venture-advanced-nuclear-fuel\" target=\"_blank\">agreement</a> with AREVA NP in&nbsp;North America.</li><li><a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a> <font color='green'>+11%</font>&nbsp;<a href=\"https://seekingalpha.com/pr/16931606-hinojosa-transforms-digital-packaging-production-high-volume-high-quality-multi-shift-success\" target=\"_blank\">successful production</a> using the world&rsquo;s first EFI&nbsp;Nozomi C18000&nbsp;single-pass ultra-high-speed corrugated packaging press.</li><li>WPCS <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16931982-wpcs-dropcar-announce-definitive-merger-agreement\" target=\"_blank\">agreement</a> with DropCar.</li><li><a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='green'>+9%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3293748-g-iii-apparel-beats-0_11-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293781-premarket-analyst-healthcare\" target=\"_blank\">positive analyst</a> action.</li><li><a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293818\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$VSTM $VYGR $SRPT - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3293818-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3293818-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293816\" data-ts=\"1504704259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293816-catalyst-bios-hemophilia-b-candidate-cb-2679d-shows-encouraging-action-in-early-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio&#39;s hemophilia B candidate CB 2679d shows encouraging action in early-stage study; shares ahead 7% premarket</a></h4><ul><li>Thinly traded nano cap Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16932309-catalyst-biosciences-announces-positive-factor-ix-clinical-data\" target=\"_blank\">announcement </a>of positive results from a Phase 1/2 proof-of-concept study assessing CB 2679d in patients with severe hemophilia B.</li><li>An intravenous dose of CB 2679d was ~22x more potent that an intravenous dose of Pfizer's <a href=\"http://www.benefix.com/\" target=\"_blank\">BeneFix </a>[coagulation Factor IX (recombinant)]. The average time in circulation also favored CB 2679d, 34 hours versus 25 hours.</li><li>Interim top-line data from the South Korea-based study should be available by year-end with complete results expected in Q1 2018.</li><li>CB 2679d is a next-generation coagulation Factor IX variant that has a longer duration of action than other Factor IX products.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293816\" data-linked=\"Catalyst Bio&#39;s hemophilia B candidate CB 2679d shows encouraging action in early-stage study; shares ahead 7% premarket\" data-tweet=\"$CBIO - Catalyst Bio&#39;s hemophilia B candidate CB 2679d shows encouraging action in early-stage study; shares ahead 7% premarket https://seekingalpha.com/news/3293816-catalyst-bios-hemophilia-b-candidate-cb-2679d-shows-encouraging-action-in-early-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3293816-catalyst-bios-hemophilia-b-candidate-cb-2679d-shows-encouraging-action-in-early-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293813\" data-ts=\"1504703770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VYGR\" target=\"_blank\">VYGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293813-voyagers-vy-aadc01-shows-encouraging-results-in-early-stage-parkinsons-study-shares-ahead-27\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Voyager&#39;s VY-AADC01 shows encouraging results in early-stage Parkinson&#39;s study; shares ahead 27% premarket</a></h4><ul><li>Thinly traded micro cap Voyager Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a>) is up&nbsp;<font color='green'>27%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16932045-voyager-therapeutics-announces-positive-results-ongoing-phase-1b-trial-vy-aadc01-advanced\" target=\"_blank\">announcement </a>of positive results from a Phase 1 clinical trial assessing gene therapy VY-AAD01 in patients with advanced Parkinson's disease &#40;PD&#41;.</li><li>The results showed durable, dose-dependent and time-dependent improvements across a range of motor function metrics after one dose. Patients in cohort 3 achieved clinically meaningful improvements in motor symptoms with lower doses of their oral PD medications, including levodopa. This is a very positive development since the long-term use of levodopa has its own unwanted side effects such as dyskinesia (involuntary movement disorder). Updated results will be reported in Q1 2018.</li><li>A Phase 2/3 study will be initiated in Q4 with patient dosing to commence in H1 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293813\" data-linked=\"Voyager&#39;s VY-AADC01 shows encouraging results in early-stage Parkinson&#39;s study; shares ahead 27% premarket\" data-tweet=\"$VYGR - Voyager&#39;s VY-AADC01 shows encouraging results in early-stage Parkinson&#39;s study; shares ahead 27% premarket https://seekingalpha.com/news/3293813-voyagers-vy-aadc01-shows-encouraging-results-in-early-stage-parkinsons-study-shares-ahead-27?source=tweet\" data-url=\"https://seekingalpha.com/news/3293813-voyagers-vy-aadc01-shows-encouraging-results-in-early-stage-parkinsons-study-shares-ahead-27\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293812\" data-ts=\"1504703468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293812-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/TRVG' title='Trivago'>TRVG</a>&nbsp;<font color='red'>-27%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293788-trivago-freefall-lowering-guidance\" target=\"_blank\">lowering</a> revenue guidance.</li><li><a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a>&nbsp;<font color='red'>-16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293797-ignyta-track-h2-2018-nda-filing-lung-cancer-med-entrectinib-shares-11-percent-premarket\" target=\"_blank\">providing</a> update on Entrectinib ROS1 lung cancer development program.</li><li><a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293732-jinkosolar-holding-misses-0_41-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293765-francescas-beats-0_01-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293667-dave-and-busters-beats-0_02-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3293812\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$TRVG $RXDX $JKS - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3293812-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3293812-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293803\" data-ts=\"1504702764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293803-csx-down-1_5-after-trimming-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX down 1.5% after trimming outlook</a></h4><ul><li>Noting \"operating challenges\" in July and August, <a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> sees full-year EPS growth of 20%-25% vs. roughly 25% previously expected. Free cash flow before dividends (and excluding restructuring charges) is still seen at about $1.5B. About $1.3B of the $1.5B buyback program has been completed.</li><li>CEO Hunter Harrison: \"CSX has made very good progress in the last 60 days in transitioning its operating model to Precision Scheduled Railroading ...&nbsp;The railroad is now returning to a normal operating rhythm, and our performance metrics are improving.\"</li><li>CFO Frank Lonegro is currently presenting at an investor conference. <a href=\"http://investors.csx.com\" target=\"_blank\">Webcast and slides are here</a>.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16932265-b-csx-b-reports-improved-progress-implementing-precision-scheduled-railroading\" target=\"_blank\">Press Release</a></li><li>Shares&nbsp;<font color='red'>-1.5%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3293803\" data-linked=\"CSX down 1.5% after trimming outlook\" data-tweet=\"$CSX - CSX down 1.5% after trimming outlook https://seekingalpha.com/news/3293803-csx-down-1_5-after-trimming-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3293803-csx-down-1_5-after-trimming-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293797\" data-ts=\"1504702506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RXDX\" target=\"_blank\">RXDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293797-ignyta-on-track-for-h2-2018-nda-filing-for-lung-cancer-med-entrectinib-shares-down-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ignyta on track for H2 2018 NDA filing for lung cancer med entrectinib; shares down 11% premarket</a></h4><ul><li>Investors appear disappointed with Ignyta's (NASDAQ:<a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a>) <a href=\"https://seekingalpha.com/pr/16932230-ignyta-provides-regulatory-update-entrectinib-ros1-lung-cancer-development-program\" target=\"_blank\">update </a>on lead candidate entrectinib. Shares are down&nbsp;<font color='red'>11%</font>&nbsp;premarket, albeit on average volume.</li><li>The company says written guidance from the FDA confirmed that data from completed and ongoing studies will be sufficient to support a New Drug Application &#40;NDA&#41; for ROS1 fusion-positive non-small cell lung cancer &#40;NSCLC&#41;, expected in H2 2018 to allow 12 months of follow-up on all responders in the dataset.</li><li><a href=\"http://ignyta.com/entrectinib-trk-inhibitor/\" target=\"_blank\">Entrectinib</a>, a selective tyrosine kinase inhibitor, is being developed for the treatment of a variety of tumor types.&nbsp;<a href=\"https://en.wikipedia.org/wiki/Tyrosine_kinase\" target=\"_blank\">Tyrosine kinase</a>&nbsp;is an enzyme that serves as an \"on/off\" switch in many cellular functions. If stuck \"on\" unregulated cell growth occurs.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3261340-ignyta-advancing-lead-product-candidate-entrectinib-shares-ahead-7-percent\" target=\"_blank\">Ignyta advancing lead product candidate entrectinib; shares ahead 7%</a> (April 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293797\" data-linked=\"Ignyta on track for H2 2018 NDA filing for lung cancer med entrectinib; shares down 11% premarket\" data-tweet=\"$RXDX - Ignyta on track for H2 2018 NDA filing for lung cancer med entrectinib; shares down 11% premarket https://seekingalpha.com/news/3293797-ignyta-on-track-for-h2-2018-nda-filing-for-lung-cancer-med-entrectinib-shares-down-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3293797-ignyta-on-track-for-h2-2018-nda-filing-for-lung-cancer-med-entrectinib-shares-down-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293788\" data-ts=\"1504700550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRVG\" target=\"_blank\">TRVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293788-trivago-in-freefall-after-lowering-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trivago in freefall after lowering guidance</a></h4><ul> <li>Trivago (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVG' title='Trivago'>TRVG</a>) slumps after lowering revenue guidance.</li> <li>The online travel company now expects revenue growth of 40% this year after initially guiding for 50% growth.</li> <li>Management cites the negative impact on revenue per qualified referral in making the algorithmic adjustment. \"Due to the speed with which the above RPQR slowdown unfolded we were unable to pull back planned television advertising spend quickly enough to prevent overspend,\" reads the company's <a href=\"https://seekingalpha.com/pr/16931983-trivago-updates-full-year-guidance-2017-expects-results-softer-planned\" target=\"_blank\">release</a>.</li> <li>TRVG <font color='red'>-22.97%</font> premarket to $11.50 vs. a 52-week trading range of $10.88 to $24.27.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293788\" data-linked=\"Trivago in freefall after lowering guidance\" data-tweet=\"$TRVG - Trivago in freefall after lowering guidance https://seekingalpha.com/news/3293788-trivago-in-freefall-after-lowering-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3293788-trivago-in-freefall-after-lowering-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293784\" data-ts=\"1504700227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IAG\" target=\"_blank\">IAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293784-iamgold-upgraded-cibc-saramacca-resource-called-game-changer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iamgold upgraded at CIBC as Saramacca resource called &quot;game changer&quot;</a></h4><ul>     <li>IAMGOLD&nbsp;(NYSE:<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a>) <font color='green'>+2.1%</font>&nbsp;premarket after CIBC <a href=\"https://www.streetinsider.com/Analyst+Comments/CIBC+Upgrades+IAMGOLD+%28IAG%29+to+Outperformer+Citing+%22Game+Changer%22/13267690.html\" target=\"_blank\">upgrades</a> shares to Outperform from Neutral with an $8.50 price target, raised from $6.50, calling the new Saramacca resource \"a game changer\" for the company that will drive lower costs and better valuation at the Rosebel mine.</li>     <li>IAG said late yesterday that Saramacca <a href=\"https://seekingalpha.com/pr/16931723-iamgold-confirms-significant-gold-discovery-exceeding-initial-targets-saramacca-strategically\" target=\"_blank\">exceeds its initial targets</a>, as the resource estimate comprises 14.4M metric tons of indicated  resources averaging 2.2 grams of gold per ton for 1.02M oz.  and 13.6M metric tons of inferred resources averaging 1.18 grams of  gold per ton for 518K oz.</li>     <li>CIBC says Saramacca will add more than 200K oz./year of production at Rosebel and improve cash costs to ~$625/oz. for 2020-23, and incorporating Saramacca  could increase Rosebel&rsquo;s net present value by 32% - or the whole company&rsquo;s NPV by 10% to $6.34/share - at current spot commodity prices.</li>     <li>The firm says the stock \"still presents reasonable value\" even after the recent  outperformance, trading at 1.1x price/NPV vs. peer averages of 1.2x for mid-tier gold producers and 1.7x for senior gold miners at current prices.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293784\" data-linked=\"Iamgold upgraded at CIBC as Saramacca resource called &quot;game changer&quot;\" data-tweet=\"$IAG - Iamgold upgraded at CIBC as Saramacca resource called &quot;game changer&quot; https://seekingalpha.com/news/3293784-iamgold-upgraded-cibc-saramacca-resource-called-game-changer?source=tweet\" data-url=\"https://seekingalpha.com/news/3293784-iamgold-upgraded-cibc-saramacca-resource-called-game-changer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293783\" data-ts=\"1504700061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293783-united-continental-falls-after-guidance-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Continental falls after guidance update</a></h4><ul> <li>United Continental (NASDAQ:<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a>) updates guidance ahead of an investor presentation today at the Cowen and Company Global Transportation Conference.</li> <li>The airline company cites Hurricane Harvey, pricing issues and geopolitical tensions as factors for Q3.</li> <li>Passenger revenue per available seat mile is expected to fall in a range of -3% to -5% during the quarter vs. -1% to +1% prior estimate. United's expected fuel price per gallon is anticipated to rise to $1.72 to $1.77 from $1.56 to $1.61. Capacity growth of 3.0% to 3.5% is seen.</li> <li>United notes that the Houston airport impact could roll into Q4.</li>  <li><a href=\"https://seekingalpha.com/filing/3688711\" target=\"_blank\">SEC Form 8-K </a></li> <li>UAL <font color='red'>-2.78%</font> premarket to $59.40.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293783\" data-linked=\"United Continental falls after guidance update\" data-tweet=\"$UAL - United Continental falls after guidance update https://seekingalpha.com/news/3293783-united-continental-falls-after-guidance-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3293783-united-continental-falls-after-guidance-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293779\" data-ts=\"1504699478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSS\" target=\"_blank\">KSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293779-kohls-higher-after-announcing-amazon-store-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kohl&#39;s higher after announcing Amazon store deal</a></h4><ul> <li>Kohl's (NYSE:<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a>)&nbsp;announces a new Amazon smart home experience will be       available in dedicated space at 10 select stores across the Los Angeles and Chicago       areas. The progam begins in October.</li><li>The company calls the 1K-square foot Amazon smart home spaces within its stores a       first-of-its-kind experience where customers can purchase Amazon       devices, accessories and smart home devices and services directly from       Amazon.</li>     <li>\"We believe in the power of our store portfolio and know that our future       as a best-in-class omnichannel retailer will be driven by how inventive,       compelling and unique we can make our store experience,&rdquo; says Kohl's chief merchandising officer&nbsp;Michelle       Gass.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16932038-kohl-s-announces-new-amazon-smart-home-experience-kohl-s-stores\" target=\"_blank\">Press Release</a></li><li>Shares of Kohl's&nbsp;<font color='green'>+1.51%</font>&nbsp;premarket to $41.00.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293779\" data-linked=\"Kohl&#39;s higher after announcing Amazon store deal\" data-tweet=\"$KSS - Kohl&#39;s higher after announcing Amazon store deal https://seekingalpha.com/news/3293779-kohls-higher-after-announcing-amazon-store-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3293779-kohls-higher-after-announcing-amazon-store-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293771\" data-ts=\"1504698872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293771-sareptas-golodirsen-shows-treatment-effect-in-early-stage-study-shares-ahead-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta&#39;s golodirsen shows treatment effect in early-stage study; shares ahead 17% premarket</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) is up&nbsp;<font color='green'>17%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16932053-sarepta-therapeutics-announces-positive-results-study-evaluating-gene-expression-dystrophin\" target=\"_blank\">announcement </a>of positive results from a Phase 1/2 study (4053-101) assessing golodirsen (SRP-4053) in 53 boys with Duchenne muscular dystrophy amenable to skipping exon 53.</li><li>All 25 boys in Part 2 of the study experienced an increase in skipping exon 53 over baseline levels at week 48. Specifically, mean dystrophin protein increased to 1.019 percent of normal compared to a mean baseline of 0.095 percent of normal (p&lt;0.001) determined via biopsies of the bicep muscle.</li><li>Complete results will be submitted for presentation at a future medical conference.</li><li>The FDA <a href=\"https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm521263.htm\" target=\"_blank\">approved </a>EXONDYS 51, for DMD boys amenable to exon 51 skipping, a year ago.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293771\" data-linked=\"Sarepta&#39;s golodirsen shows treatment effect in early-stage study; shares ahead 17% premarket\" data-tweet=\"$SRPT - Sarepta&#39;s golodirsen shows treatment effect in early-stage study; shares ahead 17% premarket https://seekingalpha.com/news/3293771-sareptas-golodirsen-shows-treatment-effect-in-early-stage-study-shares-ahead-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293771-sareptas-golodirsen-shows-treatment-effect-in-early-stage-study-shares-ahead-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293768\" data-ts=\"1504698085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRAN\" target=\"_blank\">FRAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293768-francescas-revises-fy2017-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Francesca&#39;s revises FY2017 guidance</a></h4><ul>     <li>Francesca's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a>)&nbsp;reports comparable sales fell 3% in <a href=\"https://seekingalpha.com/pr/16932109-francesca-s-reports-second-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Q2</a> due to a decrease in boutique conversion rates.</li>     <li>Merchandise category sales:&nbsp;Apparel: $65.4M (+5%); Jewelry: $25.56M (+1%);&nbsp;Accessories: $14.74M (+6%);&nbsp;Gifts: $12.84M (-3%).</li>     <li>Gross margin rate slipped 50 bps to 46.3%.</li>     <li>SG&amp;A expense rate up 440 bps to 36.3%.</li>     <li>Operating margin rate declined 490 bps to 10%.</li>     <li>Inventory +4.2% Y/Y to $34.04M.</li>     <li>Boutique count +40 Y/Y to 692.</li>     <li><b>Q3 Guidance</b>:&nbsp;Net sales: $105M to $109M; Comparable sales:&nbsp;decrease in the mid- to high-teens; EPS:&nbsp;$0.00 to $0.05.</li>     <li><b>FY2017 Guidance</b>: Net sales: $481M to $491M;&nbsp;Comparable-store sales:&nbsp;high-single digit decrease;&nbsp;EPS: $0.71 to $0.81; Shares outstanding: 36.5M; Tax&nbsp;rate: 38.3%;&nbsp;Capital expenditure: $30M to $33M; New boutiques: ~60 to 65.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293768\" data-linked=\"Francesca&#39;s revises FY2017 guidance\" data-tweet=\"$FRAN - Francesca&#39;s revises FY2017 guidance https://seekingalpha.com/news/3293768-francescas-revises-fy2017-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3293768-francescas-revises-fy2017-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293766\" data-ts=\"1504697801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293766-novo-nordisk-settles-u-s-victoza-suit-for-58_7m-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novo Nordisk settles U.S. Victoza suit for $58.7M; shares up 1% premarket</a></h4><ul><li>Novo Nordisk (NYSE:<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://www.bloomberg.com/news/articles/2017-09-05/u-s-sues-novo-nordisk-over-victoza-seeking-12-15-billion\" target=\"_blank\">settlement</a> with the U.S. Department of Justice related to the latter's investigation into the company's marketing of type 2 diabetes med Victoza (liraglutide).</li><li>The company agreed to pay $58.7M to settle eight lawsuits accusing it of downplaying warnings for the drug and misleading doctors by disguising salespeople as medical educators and paying physicians to prescribe its medications.</li><li>North America operations chief Doug Langa says, \"While we do not agree with the U.S. government&rsquo;s legal conclusions and deny any wrongdoing, we&rsquo;re pleased to have negotiated a resolution that allows the company to return its full attention to developing medicines that help improve the lives of patients.\"</li><li>The settlement consists of $12.15M for alleged violations of the Federal Food, Drug and Cosmetic Act from 2010 - 2012 and $46.5M to settle whistleblower lawsuits.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293659-novo-slips-reported-12m-u-s-lawsuit-victoza-marketing-shares-1-percent\" target=\"_blank\">Novo slips on reported $12M U.S. lawsuit over Victoza marketing, shares down 1%</a> (Sept. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293766\" data-linked=\"Novo Nordisk settles U.S. Victoza suit for $58.7M; shares up 1% premarket\" data-tweet=\"$NVO - Novo Nordisk settles U.S. Victoza suit for $58.7M; shares up 1% premarket https://seekingalpha.com/news/3293766-novo-nordisk-settles-u-s-victoza-suit-for-58_7m-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293766-novo-nordisk-settles-u-s-victoza-suit-for-58_7m-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293762\" data-ts=\"1504697119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWL\" target=\"_blank\">NWL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293762-newell-brands-lowers-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Newell Brands lowers profit guidance</a></h4><ul> <li>Newell Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/NWL' title='Newell Brands Inc.'>NWL</a>)&nbsp;lowers profit guidance to take into account the anticipated effects of       Hurricane Harvey on its&nbsp;U.S. manufactured resin businesses.</li><li>The company says that nearly all of its resin suppliers with facilities in Texas and Louisiana have       declared force majeure, with many facilities shut down for more than a       week and some still not operating.</li><li>Due to the supplier issues, the company revises its EPS guidance to $2.95 to $3.05 from $3.00 to $3.20. The outlook for 2017 sales remains the same.</li><li>NWL  <font color='red'>-6.61%</font> premarket to  $45.50.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16931960-newell-brands-revises-2017-earnings-guidance\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293762\" data-linked=\"Newell Brands lowers profit guidance\" data-tweet=\"$NWL - Newell Brands lowers profit guidance https://seekingalpha.com/news/3293762-newell-brands-lowers-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3293762-newell-brands-lowers-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293761\" data-ts=\"1504697081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293761-verastems-duvelisib-successful-in-late-stage-blood-cancer-study-shares-ahead-30-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verastem&#39;s duvelisib successful in late-stage blood cancer study; shares ahead 30% premarket</a></h4><ul><li>Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) is up&nbsp;<font color='green'>30%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16931941-verastem-announces-positive-top-line-data-pivotal-phase-3-duo-study-relapsed-refractory\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02004522?intr=Duvelisib&amp;titles=duo&amp;spons=verastem&amp;phase=2&amp;rank=1\" target=\"_blank\">DUO</a>, assessing duvelisib compared to ofatumumab (Novartis' <a href=\"https://www.hcp.novartis.com/products/arzerra/?site=43700014359017088&amp;source=01030\" target=\"_blank\">ARZERRA</a>) in patients with relapsed/refractory chronic lymphocytic leukemia &#40;CLL&#41;/small lymphocytic lymphoma &#40;SLL&#41;.</li><li>The study met its primary endpoint of a statistically valid improvement in progression-free survival &#40;PFS&#41;. Median PFS in the duvelisib cohort was 13.3 months versus 9.9 months for ofatumumab (p&lt;0.0001). The hazard ratio was 0.52, meaning the duvelisib group experienced 48% less risk of cancer progression or death. Median PFS in a subgroup of patients with 17p deletion was 12.7 months compared to 9.0 months for ofatumumab (p=0.0011).</li><li>The company plans to file its U.S. marketing application in H1 2018.</li><li>Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.</li><li>The company will host a conference call this morning at 8:00 am ET to discuss the results.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277990-verastem-continues-move-shares-ahead-20-percent\" target=\"_blank\">Verastem continues up move, shares ahead 20%</a> (July 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293761\" data-linked=\"Verastem&#39;s duvelisib successful in late-stage blood cancer study; shares ahead 30% premarket\" data-tweet=\"$VSTM - Verastem&#39;s duvelisib successful in late-stage blood cancer study; shares ahead 30% premarket https://seekingalpha.com/news/3293761-verastems-duvelisib-successful-in-late-stage-blood-cancer-study-shares-ahead-30-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293761-verastems-duvelisib-successful-in-late-stage-blood-cancer-study-shares-ahead-30-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293755\" data-ts=\"1504696517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIII\" target=\"_blank\">GIII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293755-g-iii-apparel-raises-fy2018-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G-III Apparel further raises FY2018 guidance</a></h4><ul><li>G-III Apparel (NASDAQ:<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a>) reports net sales rose 21.6% in <a href=\"https://seekingalpha.com/pr/16932002-g-iii-apparel-group-ltd-announces-second-quarter-fiscal-2018-results\" target=\"_blank\">Q2</a>&nbsp;as it includes net sales of DKNY and Donna Karan products.</li><li>Gross margin rate improved 250 bps to 37.7%.</li><li>SG&amp;A expense rate increased 180 bps to 36.4%.</li><li>Inventory +15% to $655.27M.</li><li><b>Q3 Guidance</b>: Net sales: ~$1.03B; Net income: $69M to $73M; Diluted EPS: $1.36 to $1.46; Adjusted net income: $73M to $78M;&nbsp;Adjusted EPS: $1.45 to $1.55.</li><li><b>FY2018 Guidance</b>:&nbsp;Net sales: ~$2.8B; D&amp;A: $40M;&nbsp;Interest and financing charges, net: $44.4M; Income tax expense: $32M to $36M;&nbsp;Net income: $56M to $60M; Diluted EPS: $1.11 to $1.21; Adjusted net income: ~$64M to $69M; Adjusted EPS: $1.28 to $1.38; Adjusted EBITDA: $180M to $188M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293755\" data-linked=\"G-III Apparel further raises FY2018 guidance\" data-tweet=\"$GIII - G-III Apparel further raises FY2018 guidance https://seekingalpha.com/news/3293755-g-iii-apparel-raises-fy2018-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3293755-g-iii-apparel-raises-fy2018-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293743\" data-ts=\"1504695439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOS\" target=\"_blank\">SHOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293743-on-sears-hometown-and-outlet-stores-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Sears Hometown and Outlet Stores&#39; Q2</a></h4><ul><li>Sears Hometown and Outlet (NASDAQ:<a href='https://seekingalpha.com/symbol/SHOS' title='Sears Hometown and Outlet Stores, Inc.'>SHOS</a>) reports comparable-store sales squeezed 2.1% in <a href=\"https://seekingalpha.com/pr/16931892-sears-hometown-outlet-stores-inc-reports-second-quarter-2017-results\" target=\"_blank\">Q2</a>.</li><li>Comp for Hometown and Outlet slipped 0.9% and 5%.</li><li>Segment sales: Hometown:$347.64M (-12.3%); Outlet sales: $142.35M (-10.9%).</li><li>Gross margin rate fell 180 bps to 18.8%.</li><li>SG&amp;A expense rate up 210 bps to 23.5%.</li><li>Inventory -16.5% to $356.89M.</li><li>Store count -17% Y/Y to 932.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293743\" data-linked=\"More on Sears Hometown and Outlet Stores&#39; Q2\" data-tweet=\"$SHOS - More on Sears Hometown and Outlet Stores&#39; Q2 https://seekingalpha.com/news/3293743-on-sears-hometown-and-outlet-stores-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3293743-on-sears-hometown-and-outlet-stores-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":59,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}